Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518).

Jensen, A D; Münter, M W; Bischoff, H; Haselmann, R; Timke, C; Krempien, R; Sterzing, F; Nill, S; Heeger, S; Hoess, A; Haberkorn, U; Huber, P E; Steins, M; Thomas, M; Debus, J; Herfarth, K K

Jensen, A D; Münter, M W; Bischoff, H; Haselmann, R; Timke, C; Krempien, R; Sterzing, F; Nill, S; Heeger, S; Hoess, A; Haberkorn, U; Huber, P E; Steins, M; Thomas, M; Debus, J; Herfarth, K K.

Affiliation

Jensen AD; Dept. of Radiation Oncology, Clinical Radiology, University of Heidelberg Medical School, INF 400, 69120 Heidelberg, Germany. a.jensen@dkfz.de

BMC Cancer ; 6: 122, 2006 May 08.

Article in En | MEDLINE | ID: mdl-16681848

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Radiotherapy, Intensity-Modulated; Adult; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal, Humanized; Antineoplastic Agents/adverse effects; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/radiotherapy; Cetuximab; Combined Modality Therapy/methods; ErbB Receptors/antagonists & inhibitors; Feasibility Studies; Female; Humans; Lung Neoplasms/drug therapy; Lung Neoplasms/radiotherapy; Male; Prospective Studies

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Radiotherapy, Intensity-Modulated / Lung Neoplasms / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Guideline / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Year: 2006 Type: Article

Fulltext

XML

PubMed Links

Search on Google